We analyzed diagnosis, relapse and follow-up samples of 5 out of 256 CN-AML patients, who tested negative for FLT3 ITD at diagnosis by routine approaches, but carried FLT3 ITD at relapse or disease progression. Here, FLT3 is linked to acute myeloid leukemia.